PSP Swiss Property AG (PSPSY) Discusses Richtipark Disposal and Increase in EBITDA Guidance Transcript
Retail investing has long proved a tantalizing prospect for private equity players. Traditionally a space for limited partners with huge asset pools, like family offices, endowments, pension programs, high net worth individuals (HWNI) and more, private equity funds saw their doors open just slightly more to retail investors in May.
PSP is a strong sell due to persistent underperformance versus SPY and its high expense ratio, eroding any potential alpha. Private equity exposure can be achieved more efficiently by directly holding top players like Blackstone, KKR, and Ares, avoiding ETF fees. PSP's asset mix dilutes returns by combining best-in-class managers with weaker players, resulting in subpar performance.
The investing landscape is littered with vehicles that have auras of exclusivity. It feels as though it's off-limits to ordinary investors.
The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025.
The Invesco Global Listed Private Equity ETF offers exposure to the private markets industry via publicly traded vehicles. PSP has delivered relatively weak historical performance for investors relative to the broader market. The ETF is highly diversified and includes significant exposure to BDCs.